Endologix Inc. (Nasdaq: ELGX) must conduct a confirmatory clinical study for its Nellix Endovascular Aneurysm Sealing System. Shares of the medical device maker plummeted $2.47 to close at $4.26.
Endologix must conduct confirmatory clinical study
May 18, 2017 at 16:57 PM EDT
